Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

HaemaLogiX

HaemaLogiX
PRIVATE STATUS
1-10 EMPLOYEES
Accelerator/Inc LATEST DEAL TYPE
1 INVESTORS
Description

Developer of novel immuno-oncology and immune-therapies intended for the treatment of haematologic malignancies and auto-immune diseases. The company's mmuno-oncology and immune-therapies enables blood cancers patient to have extended survival time from the disease.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Suite 145
  • 4 Cornwallis Street
  • Eveleigh, New South Wales 2015
  • Australia

+61 (02) 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore HaemaLogiX’s full profile, request a free trial.

HaemaLogiX Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

HaemaLogiX Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Cicada Innovations Accelerator/Incubator Minority 000 0000 000000 0

HaemaLogiX Executive Team (3)

Name Title Board
Seat
Contact
Info
Bryce Carmine Chief Executive Officer & Chairman
Dimitra Korkidas Chief Financial Officer and Company Secretary
Rosanne Dunn Ph.D Director of Vice President, Clinical Research & Product Development and Board Member

HaemaLogiX Board Members (3)

Name Representing Role Since Contact
Info
Alan Liddle HaemaLogiX Board Member 000 0000
Bryce Carmine HaemaLogiX Chief Executive Officer & Chairman 000 0000
John Cullity HaemaLogiX Board Member 000 0000